NASDAQ:BBIO BridgeBio Pharma Q3 2026 Earnings Report $65.80 -0.17 (-0.26%) Closing price 09/30/2026 04:00 PM EasternExtended Trading$66.12 +0.32 (+0.49%) As of 09/30/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast BridgeBio Pharma EPS ResultsActual EPSN/AConsensus EPS -$0.61Beat/MissN/AOne Year Ago EPSN/ABridgeBio Pharma Revenue ResultsActual RevenueN/AExpected Revenue$268.99 millionBeat/MissN/AYoY Revenue GrowthN/ABridgeBio Pharma Announcement DetailsQuarterQ3 2026Date10/28/2026TimeAfter Market ClosesConference Call DateWednesday, October 28, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile BridgeBio Pharma Earnings HeadlinesHead-To-Head Survey: BridgeBio Pharma (NASDAQ:BBIO) vs. MannKind (NASDAQ:MNKD)September 30 at 4:44 AM | americanbankingnews.comThe Bull Case For BridgeBio Pharma (BBIO) Could Change Following New ATTR Data Versus TafamidisSeptember 27, 2026 | finance.yahoo.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now. | Stansberry Research (Ad)BridgeBio Pharma (BBIO) Stock Looks Reasonable As Fresh Acoramidis Data LandsSeptember 27, 2026 | finance.yahoo.comBridgeBio Pharma, Inc. - Acoramidis Demonstrates Real-World Benefit versus Tafamidis in ATTR-CM, Reducing Risk of Clinical WorseningSeptember 24, 2026 | marketscreener.comMBridgeBio Publishes Data Validating Acoramidis As ATTR-CM Therapy Over TafamidisSeptember 23, 2026 | rttnews.comSee More BridgeBio Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BridgeBio Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BridgeBio Pharma and other key companies, straight to your email. Email Address About BridgeBio PharmaBridgeBio Pharma (NASDAQ:BBIO) is a biotechnology company focused on discovering, developing and commercializing medicines for genetically driven diseases. The company uses its drug discovery and development platform to advance therapies across areas including rare diseases, genetic disorders and precision oncology, with programs designed to address the underlying biological causes of disease. BridgeBio operates through a collection of subsidiary companies and development programs. Its portfolio has included therapies for cardiovascular, endocrine, neurological and oncological conditions. The company’s acoramidis, marketed in the United States as Attruby, was approved by the U.S. Food and Drug Administration in 2024 for the treatment of adults with cardiomyopathy caused by transthyretin-mediated amyloidosis. Founded in 2015, BridgeBio is headquartered in Palo Alto, California, and conducts research, clinical development and commercial activities through its subsidiaries and collaborations in the United States and international markets. The company was co-founded and is led by Neil Kumar, who serves as chief executive officer. Its products and investigational therapies are developed for patients with serious conditions that often have limited or no approved treatment options.View BridgeBio Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?CarMax Just Gave Investors a Better Reason to Believe in the TurnaroundArhaus Has New Momentum—Could Other Furniture Stocks Be Next?Bernstein Downgrades 3 Cybersecurity Stocks: How Concerned Should Investors Be?Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks Upcoming Earnings NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
